Usefulness of Red Cell Distribution Width as a Prognostic Marker in Pulmonary Hypertension††Conflicts of interest: Dr. Gomberg-Maitland has received research grant support from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; CoTherix, Inc., South San Francisco, California; Encysive Pharmaceuticals Inc., Houston, Texas; Gilead Sciences Inc., Foster City, California; Eli Lilly/ICOS, Indianapolis, Indiana; Pfizer Inc., New York, New York; and United Therapeutics, Silver Spring, Maryland. Dr. Gomberg-Maitland has served as a consultant and/or on advisory boards for Encysive Pharmaceuticals Inc., Gilead Sciences Inc., Pfizer Inc., and United Therapeutics. Dr. Shah has received research grant support from Actelion Pharmaceuticals Ltd. (Entelligence Young Investigator Award) and is also the recipient of a Scientist Development Grant from the American Heart Association, Dallas, Texas.
Year: 2009
Type: article
Study design: Observational Study
Institutions: University of Chicago, Northwestern University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: red cell distribution width, pulmonary hypertension, prognostic factors, mortality prediction, pulmonary arterial hypertension, right heart failure, hemoglobin, mean corpuscular volume, blood urea nitrogen, phosphodiesterase inhibitors, diuretics, connective tissue diseases, diabetes mellitus, NT-proBNP-guided therapy
Open Access status: bronze
OpenAlex ID: W1998740550
